0000000000326037

AUTHOR

C. Gridelli

showing 3 related works from this author

Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phas…

1996

Purpose : To compare mitomycin C plus vindesine plus etoposide (MEV) vs. mitomycin C plus vindesine plus cisplatin (MVP) in the treatment of stage IV non-small-cell lung cancer. Patients and methods : 204 patients were entered in a phase III multicentre randomised trial from June 1990 to December 1994 and stratified according to the ECOG performance status (0-1 vs. 2). MVP was given in the following dosages : mitomycin C 8 mg/m 2 + vindesine 3 mg/m 2 + cisplatin 100 mg/m 2 i.v. day 1 and vindesine 3 mg/m 2 i.v. day 8 with cycles repeated every 4 weeks. MEV was given in the following dosages : mitomycin C 8 mg/m 2 + vindesine 3 mg/m 2 i.v. day I and etoposide 100 mg/m 2 i.v. days 1 to 3 with…

Chemotherapymedicine.medical_specialtyPalliative carePerformance statusbusiness.industrymedicine.medical_treatmentMitomycin CHematologymedicine.diseaseGastroenterologyOncologyInternal medicinemedicineVindesineNuclear medicinebusinessLung cancerSurvival rateEtoposidemedicine.drug
researchProduct

94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations

2021

Oncologybusiness.industryMedicineHematologyComputational biologybusinessRanking (information retrieval)Annals of Oncology
researchProduct

167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryNeutropeniamedicine.diseaseTreatment efficacylaw.inventionPooled analysisOncologyRandomized controlled trialChemotherapy inducedlawInternal medicinemedicineNon small cellLung cancerbusinessJournal of Thoracic Oncology
researchProduct